# ArcaScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arcascience

- Industry: Healthcare IT
- Headquarters: Paris, France
- Website: www.arcascience.ai
- Total disclosed funding: $7M
- Latest round: Seed (Sep 2, 2025)
- Investors on record: 5

## About

Based in France, ArcaScience SAS specializes in advanced AI-driven solutions aimed at improving drug safety and efficacy across multiple medical fields.Founded in 2018 and headquartered in Paris, France, ArcaScience SAS develops innovative solutions for the biopharmaceutical industry. The company has secured The company has secured EUR 6 million in seed funding led by new investor The Moon Venture, with participation from other new investors Bpifrance, and Pléiade Venture. Returning investor Plug and Play Ventures and Akka also participated in the round .ArcaScience specializes in advanced artificial intelligence-driven solutions designed to enhance drug safety and efficacy across various medical fields. The company's core offerings include AI-assisted benefit-risk prediction, safety monitoring reports, endpoint discovery, and Key Opinion Leader (KOL) identification. These products aim to streamline the drug development process by leveraging a comprehensive patient-centric database enriched with over 100 billion data points. ArcaScience's solutions are particularly beneficial for clinicians and safety specialists, enabling them to make informed decisions regarding drug efficacy and safety while minimizing risks. The firm serves a global clientele, including notable biopharmaceutical companies and research institutions across North America, Europe, and Asia, promoting patient-centered approaches in clinical trials and real-world studies.ArcaScience generates revenue primarily through B2B transactions with biopharmaceutical companies and healthcare institutions utilizing its AI-driven insights and analytics services. The company establishes partnerships and subscription-based models to provide its suite of products, including the flagship Benefit-Risk Prediction study and SafetyShield reports. Clients engage with ArcaScience for tailored studies, ongoing safety monitoring, and endpoint analysis, facilitating robust clinical trial planning and execution. The transaction structure typically involves direct agreements with clients, emphasizing the delivery of precise, actionable data that aids in drug development and regulatory compliance.ArcaScience intends to utilize the recently raised EUR 6 million in funding to support its expansion into the United States and United Kingdom, drive the establishment of a new benchmark in drug evaluation, enable the launch of its first patient-focused solution, and facilitate the appointment of a Chief Medical Officer. The company plans to develop new AI tools focused on drug safety monitoring, with anticipated launches in the coming year. Additionally, it aims to expand its presence in key markets in North America and Asia by 2024, targeting collaborations with more biopharmaceutical firms to broaden its influence in the healthcare sector.

## Funding rounds

- Seed, Sep 2, 2025, $7M — Bpifrance, Plug and Play, Pléiade Venture, The Moon Venture, Akka

## Investors

- Bpifrance — Seed
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Seed
- Pléiade Venture — Seed
- The Moon Venture — Seed
- Akka — Seed